Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.47 |
| ▸ | MIF | P14174 | 3/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | BACH1 | O14867 | 1/20 | 0.41 |
| ▸ | MAFK | O60675 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17519951 | 0.94 | TSHR (0.52) | TSHRKEAP1NFE2L2MIFNAAA | |
| SCHEMBL2824773 | 0.92 | TSHR (0.50) | TSHRKEAP1NFE2L2MIFNAAA | |
| SCHEMBL13123489 | 0.92 | TSHR (0.50) | TSHRKEAP1NFE2L2MIFNAAA | |
| SCHEMBL11177812 | 0.92 | TSHR (0.50) | TSHRKEAP1NFE2L2MIFNAAA | |
| SCHEMBL1364810 | 0.88 | — | — | |
| SCHEMBL3403179 | 0.82 | TSHR (0.56) | TSHRALDH1A1LMNA | |
| SCHEMBL3083780 | 0.81 | CYP1A2 (0.50) | TSHRKEAP1NFE2L2MIFNAAA | |
| SCHEMBL10695420 | 0.77 | TSHR (0.50) | TSHRALDH1A1LMNA | |
| SCHEMBL25332582 | 0.77 | — | — | |
| SCHEMBL13667792 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | SOCIETE DE CONSEILS DE RECHERCHES ET (FR) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270372-A1 | NOVEL DERIVATIVES OF BENZIMIDAZOLE AND IMIDAZO-PYRIDINE AND THEIR USE AS MEDICAMENTS | MC4R, MC3R, MC1R | TSHR 217/4885KEAP1 3263/4885NFE2L2 3286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.